The new therapy reduces the risk of recurrence in early breast cancer

An early breast year is the one most commonly diagnosed. What does prognosis depend on?

Early breast cancer is diagnosed in over 90% of all patients diagnosed with breast cancer. The vast majority of women come to us with early cancer. We want to cure all our patients, but each of these ladies has a different prognosis. It depends primarily on the biological subtype of breast cancer. There are crayfish more and less aggressive. The hormone-dependent carcinoma that appears to have the best prognosis is a biological subtype, occurring in approximately 70% of adults. all sick. In this group of women, however, there are patients who have a higher risk of recurrence. The factors that we are assessing are certainly also the size of the tumor. The bigger the tumor, the worse the prognosis is. The number of metastatic lymph nodes involved is another important thing we evaluate. Finally, the malignancy trait: G1, G2 or G3. The G3 feature is high malignancy and then there is certainly a greater risk of recurrence of the disease. Another factor is the Ki67 proliferation index. The higher it is, the greater the risk. We analyze all these features and evaluate what treatment the patient should receive.

What therapies are currently used to treat early breast cancer?

In Poland, in the treatment of patients with hormone-dependent breast cancer with a high risk of recurrence, we often resort to chemotherapy in addition to hormone therapy. These are patients who need more aggressive treatment for better prognosis. We start treatment with preoperative chemotherapy, surgery is performed, and radiotherapy is often introduced. The standard treatment is later hormone therapy. It may last up to 10 years.

Recently, new therapies have also been registered: abemaciclib and olaparib. Abemaciclib is a CDK4/6 inhibitor, already known as a molecule intended for patients with metastatic breast cancer. It is a drug that significantly improves the prognosis for that indication. However, there have been studies that show that the use of this therapy in combination with hormone therapy reduces relapses in patients with early breast cancer, at high risk of recurrence of the disease. It is a therapy already registered in the European Union. We are waiting for availability for our patients. The second therapeutic group are PARP inhibitors in BRCA mutation carriers, which also have an increased risk of disease recurrence. Such adjuvant therapy also reduces the risk of relapse. So we can heal more and more effectively.

Thanks for the interview.